Circulating free tumor-derived DNA to detect
Non-small cell lung cancer (NSCLC)
circulating tumor DNA
epidermal growth factor receptor (EGFR)
plasma
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
11
6
2019
pubmed:
11
6
2019
medline:
11
6
2019
Statut:
ppublish
Résumé
The non-interventional ASSESS study (NCT01785888) evaluated the utility of circulating free tumor-derived DNA (ctDNA) from plasma for epidermal growth factor receptor ( Eligible patients (stage IIIA/B/IV locally advanced/metastatic treatment-naive advanced NSCLC) provided diagnostic tissue/cytology and plasma samples. DNA extracted from tissue/cytology samples was subjected to Of the 1,311 patients enrolled in the ASSESS trial, 145 were recruited from 9 centers in France. Tumor samples from 130 patients were collected and 126 were evaluable for Data confirm ctDNA as an alternative sample for
Sections du résumé
BACKGROUND
BACKGROUND
The non-interventional ASSESS study (NCT01785888) evaluated the utility of circulating free tumor-derived DNA (ctDNA) from plasma for epidermal growth factor receptor (
METHODS
METHODS
Eligible patients (stage IIIA/B/IV locally advanced/metastatic treatment-naive advanced NSCLC) provided diagnostic tissue/cytology and plasma samples. DNA extracted from tissue/cytology samples was subjected to
RESULTS
RESULTS
Of the 1,311 patients enrolled in the ASSESS trial, 145 were recruited from 9 centers in France. Tumor samples from 130 patients were collected and 126 were evaluable for
CONCLUSIONS
CONCLUSIONS
Data confirm ctDNA as an alternative sample for
Identifiants
pubmed: 31179079
doi: 10.21037/jtd.2019.03.95
pii: jtd-11-04-1370
pmc: PMC6531756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1370-1378Déclaration de conflit d'intérêts
Conflicts of Interest: MG Denis: grants/research support/consultant for AstraZeneca, BMS, Boehringer Ingelheim, Merck, Qiagen, Roche Pharma, and Takeda. G Le Garff: clinical trials for AstraZeneca, Lilly, and Roche; all financial contributions except MUTACT study (AstraZeneca) paid by clinical research unit; board member for Novartis; invitation to congress from Air Santé, Altana, AstraZeneca (before 2012), Boehringer Ingelheim, GSK, LFB, Lilly, MSD, Pierre Fabre, and Roche. C Locher: membership on advisory board for AstraZeneca, BMS, Boehringer Ingelheim, Pfizer, and Roche; medical conferences for Novartis. M Licour: employee of AstraZeneca. N Normanno: grants/research support/consultant for AstraZeneca, Qiagen, and Roche Diagnostics. M Reck: member of the speaker’s bureau for AstraZeneca, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Hoffmann-La Roche, Lilly, and Pfizer; consultant for AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, Hoffmann-La Roche, Lilly, MSD, and Pfizer. All other authors have declared no conflicts of interest.
Références
Eur Respir J. 2001 Dec;18(6):1059-68
pubmed: 11829087
Clin Cancer Res. 2006 Dec 15;12(24):7232-41
pubmed: 17189394
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Lung Cancer. 2013 Nov;82(2):373-4
pubmed: 24007628
Br J Cancer. 2014 Jan 7;110(1):55-62
pubmed: 24263064
J Thorac Oncol. 2014 Jul;9(7):e49-50
pubmed: 24926553
J Mol Diagn. 2014 Sep;16(5):558-563
pubmed: 24994671
J Thorac Oncol. 2014 Sep;9(9):1345-53
pubmed: 25122430
Clin Cancer Res. 2015 Jul 15;21(14):3196-203
pubmed: 25829397
Future Oncol. 2015;11(11):1611-23
pubmed: 26043215
Lung Cancer. 2015 Dec;90(3):509-15
pubmed: 26494259
Lung Cancer. 2016 Jan;91:73-4
pubmed: 26612314
J Thorac Oncol. 2016 Oct;11(10):1690-700
pubmed: 27468937
J Thorac Oncol. 2016 Oct;11(10):1682-9
pubmed: 27468938
J Hematol Oncol. 2016 Sep 13;9(1):86
pubmed: 27619632
Expert Rev Mol Diagn. 2016 Dec;16(12):1251-1257
pubmed: 27737606
Cancer Chemother Pharmacol. 2016 Dec;78(6):1305-1310
pubmed: 27770237
Oncotarget. 2017 Feb 14;8(7):12501-12516
pubmed: 27980215
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
Lung Cancer. 2017 Jun;108:22-28
pubmed: 28625639
Lung Cancer. 2017 Dec;114:111-112
pubmed: 29096978